Novartis Eyes Full, $50 billion Alcon Takeover

Novartis on Jan 4 announced it was exercising its option to purchase Nestlé's remaining 52 percent stake in eye-care group Alcon for $28.1 billion. The Swiss Big Pharma will finish up paying almost $50 billion for full control of the group, given its controversial attempt to buy out the minority Alcon shareholders for a further $11.2 billion.

It came as no surprise when on January 4 Novartis AG announced it was exercising its option to purchase Nestlé's remaining 52% stake in eye-care group Alcon Inc. for $28.1 billion, or $180 per share. The Swiss Big Pharma had as good as committed to do so back in April 2008, when it bought the first tranche of 25% from Nestlé SA for $10.4 billion, or $143 per share. [See Deal] At the time, Novartis agreed to a "put" clause allowing Nestlé to compel it to buy the additional shares between early-2010 and mid-2011 at a price not exceeding $181 per share, or roughly $28 billion.

Given that Alcon's shares fell to less than half of their April 2008 value at the end of that year,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By 

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

AI In Drug Discovery: The Patent Implications

 
• By 

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By 

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By 

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.